What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study, Phase 2).

December 8, 2025Blood

Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial

View Full Paper

Ask AI

Bookmark

Authors

Single-arm trial found high response rates with Selinexor plus azacitidine in patients with MDS, suggesting effective therapy options.

The overall response rate was high at 94.4%, with significant complete response noted among patients with TP53 mutations.
Patients experienced adverse events, most commonly neutropenia and anemia, emphasizing the need for monitoring during treatment.
Selinexor acts as an oral inhibitor, providing a novel approach for treating high-risk myelodysplastic syndromes in this cohort.
Results imply the combination therapy may improve outcomes for MDS patients, highlighting a potential new standard of care.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Single-arm trial found high response rates with Selinexor plus azacitidine in patients with MDS, suggesting effective therapy options.

The overall response rate was high at 94.4%, with significant complete response noted among patients with TP53 mutations.
Patients experienced adverse events, most commonly neutropenia and anemia, emphasizing the need for monitoring during treatment.
Selinexor acts as an oral inhibitor, providing a novel approach for treating high-risk myelodysplastic syndromes in this cohort.
Results imply the combination therapy may improve outcomes for MDS patients, highlighting a potential new standard of care.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark